Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment

Headache

Volumn 52, Issue 9, 2012, Pages 1350-1361

  Perrotta, Armando ^a   Arce Leal, Natalia ^a,b   Tassorelli, Cristina ^b,c   Gasperi, Valeria ^d   Sances, Grazia ^c   Blandini, Fabio ^c   Serrao, Mariano ^e   Bolla, Monica ^c   Pierelli, Francesco ^e   Nappi, Giuseppe ^c   MacCarrone, Mauro ^f,g   Sandrini, Giorgio ^b,c  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF TERAMO   (Italy)

^g IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

endocannabinoid system; medication overuse headache; nociceptive withdrawal reflex; spinal sensitization; temporal summation

Indexed keywords

ANANDAMIDE; ENDOCANNABINOID; FATTY ACID AMIDASE;

ADULT; ANTINOCICEPTION; ARTICLE; CELL ACTIVITY; CHEMICAL ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INDUCED HEADACHE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; NEUROPHYSIOLOGY; NOCICEPTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; SENSITIZATION; SPINAL CORD; TEMPORAL SUMMATION; THROMBOCYTE; TREATMENT WITHDRAWAL; WITHDRAWAL REFLEX;

ADULT; AMIDOHYDROLASES; ANALGESICS; FEMALE; HEADACHE; HUMANS; MALE; NEURAL PATHWAYS; PAIN; PAIN THRESHOLD; REFLEX; SUBSTANCE-RELATED DISORDERS;

EID: 84867100239     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02170.x     Document Type: Article

References (40)

1. Iversen L, Chapman V,. Cannabinoids: A real prospect for pain relief? Curr Opin Pharmacol. 2002; 2: 50-55.
2. Greco R, Gasperi V, Maccarrone M, Tassorelli C,. The endocannabinoid system and migraine. Exp Neurol. 2010; 224: 85-91.
3. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM,. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83: 393-411.
4. Hohmann AG, Herkenham M,. Regulation of cannabinoid and mu opioids receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett. 1998; 252: 13-16.
5. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR,. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci. 2000; 15: 510-521.
6. Herkenham M, Lynn AB, Little MD, et al,. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990; 87: 1932-1936.
7. Maione S, Bisogno T, de Novellis V, et al,. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther. 2006; 316: 969-982.
8. Ji RR, Kohno T, Moore KA, Woolf CJ,. Central sensitization and LTP: Do pain and memory share similar mechanisms? Trends Neurosci. 2003; 26: 696-705.
9. Papanastassiou AM, Fields HL, Meng ID,. Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons. Pain. 2004; 107: 267-275.
10. Johanek LM, Simone DA,. Cannabinoid agonist, CP 55,940, prevents capsaicin-induced sensitization of spinal cord dorsal horn neurons. J Neurophysiol. 2005; 93: 989-997.
11. Strangman NM, Walker JM,. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol. 1999; 82: 472-477.
12. Petrosino S, Palazzo E, de Novellis V, et al,. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 2007; 52: 415-422.
13. Akerman S, Kaube H, Goadsby PJ,. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004; 309: 56-63.
14. Akerman S, Holland PR, Goadsby PJ,. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007; 320: 64-71.
15. Fezza F, De Simone C, Amadio D, Maccarrone M,. Fatty acid amide hydrolase: A gate-keeper of the endocannabinoid system. Subcell Biochem. 2008; 49: 101-132.
16. Greco R, Gasperi V, Sandrini G, et al,. Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia. 2010; 30: 296-302.
17. Cupini LM, Bari M, Battista N, et al,. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia. 2006; 26: 277-281.
18. Sarchielli P, Pini LA, Coppola F, et al,. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007; 32: 1384-1390.
19. Price DD,. Characteristics of second pain and flexion reflexes indicative of prolonged central summation. Exp Neurol. 1972; 37: 371-387.
20. Arendt-Nielsen L, Brennum J, Sindrup S, Bak P,. Electrophysiological and psychophysical quantification of temporal summation in the human nociceptive system. Eur J Appl Physiol Occup Physiol. 1994; 68: 266-273.
21. Sandrini G, Serrao M, Rossi P, Romaniello A, Cruccu G, Willer JC,. The lower limb flexion reflex in humans. Prog Neurobiol. 2005; 77: 353-395.
22. Woolf CJ,. Windup and central sensitization are not equivalent. Pain. 1996; 66: 105-108.
23. Perrotta A, Serrao M, Sandrini G, et al,. Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia. 2010; 30: 272-284.
24. Perrotta A, Serrao M, Tassorelli C, et al,. Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: A double-blind, placebo-controlled, cross-over study. Eur J Pain. 2011; 15: 482-490.
25. Perrotta A, Sandrini G, Serrao M, et al,. Facilitated temporal summation of pain at spinal level in Parkinson's disease. Move Disord. 2011; 26: 442-448.
26. Nappi G, Perrotta A, Rossi P, Sandrini G,. Chronic daily headache. Expert Rev Neurother. 2008; 8: 361-384. Review.
27. Centonze D, Battistini L, Maccarrone M,. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des. 2008; 14: 2370-2382.
28. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
29. Bruehl S, Harden RN, Galer BS, et al,. External validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain. 1999; 81: 147-154.
30. Cruccu G, Anand P, Attal N, et al,. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004; 11: 153-162.
31. Wolfe F, Smythe HA, Yunus MB, et al,. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990; 33: 160-172.
32. Serrao M, Rossi P, Sandrini G, et al,. Effects of diffuse noxious inhibitory controls on temporal summation of the NWR reflex in humans. Pain. 2004; 112: 353-360.
33. Maccarrone M, Del Principe D, Finazzi-Agrà A,. Endocannabinoids: New physiological co-agonists of human platelets. Thromb Haemost. 2002; 88: 165-166.
34. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agrà A,. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem. 2001; 268: 819-825.
35. Cupini LM, Costa C, Sarchielli P, et al,. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008; 30: 186-189.
36. Cravatt BF, Demarest K, Patricelli MP, et al,. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98: 9371-9376.
37. Ayzenberg I, Obermann M, Nyhuis P, et al,. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia. 2006; 26: 1106-1114.
38. Maldonado R, Valverde O, Berrendero F,. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006; 29: 225-232.
39. Calabresi P, Cupini LM,. Medication-overuse headache: Similarities with drug addiction. Trends Pharmacol Sci. 2005; 26: 62-68.
40. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH,. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A. 2004; 101: 10821-10826.